© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 13, 908-917,
July 3, 1996
© 1996 Oxford University Press
Induction of Apoptosis by Diethylstilbestrol in Hormone-Insensitive Prostate Cancer Cells
Department of Surgery, Division of Urology, Duke University and Durham VA Medical Centers NC
Department of Cell Biology, Duke University and Durham VA Medical Centers NC
Department of Ophthalmology, Duke University and Durham VA Medical Centers NC
Comprehensive Cancer Center, Division of Flow Cytometry, Duke University and Durham VA Medical Centers NC
Division of Hematology-Oncology, Department of Medicine, Duke University and Durham VA Medical Centers NC
Correspondence to present address: Robert L. Fine, M.D. Columbia University, College of Physicians and Surgeons, Rm. 20-05, Black Bldg. 650 W. 168th St. New York, NY 10032.
Background: Diethylstilbestrol (DES) and diethylstilbestrol diphosphate (DESdP) are effective agents for the treatment of advanced prostate cancers. Tumor-inhibiting effects of DES and DESdP are presumed secondary to suppression of androgen production in vivo. Little is known, however, about the direct cellular mechanisms of the tumor inhibition. Estrogens have been reported not only to stimulate growth but also to disrupt microtubule formation in prostate cancer cells. Purpose: The study was designed to examine and compare mechanisms of in vitro growth inhibition of DES and DESdP in human androgen-insensitive prostate cancer cells (DU145, 1-LN, and PC-3) and human androgen-sensitive prostate cancer cells (LNCaP) and to examine estrogen receptor modulation of such effects. Methods: The cytotoxic effects of DES and DESdP were examined in vitro by use of a standard microculture tetrazolium assay to quantitate numbers of viable cells. Immunofluorescence microscopy, DNA fragmentation analysis, and fluorescence flow cytometry were used to investigate microtubules, the induction of apoptosis, and changes in cell cycle distribution. The degree of estrogen receptor positivity of untreated and treated cells was determined by immunohistochemistry and quantitative image analysis. Results: LD50 levels (the dose at which 50% of cells are no longer viable) in the concentration range of 19–25 µM were observed for both DES and DESdP in all cell lines examined. DESdP-induced growth inhibition was found to be dependent on heat-labile phosphatases present in fetal calf serum. DES-induced cytotoxicity was not affected by the presence of 17
-estradiol, and it was not dependent on the presence of estrogen receptor. Estrogen receptor-positive cells and estrogen receptor-negative cells were equally responsive to DES. PC-3 cells stained with fluorescent anti-tubulin, phalloidin (actin stain), and 4', 6-diamidino-2-phenylindole (DNA stain) showed no inhibition of microtubules or actin filaments but revealed the presence of apoptotic bodies in the nuclei. Fluorescence flow cytometry of nuclear DNA content of propidium iodide-stained nuclei from androgen-insensitive prostate cancer cells treated with 15 or 30 µM DES or DESdP revealed an increase in relative numbers of hypodiploid (apoptotic) nuclei, a depletion of G1 and S-phase cells, and an accumulation of cells in G2/M phase. Conversely, androgen-sensitive cells contained a lower percentage of hypodiploid nuclei but no accumulation of cells in G2/M phase. Conclusions: Direct cytotoxic effects of DES in prostate cancer cells are estrogen receptor independent and do not involve disruption of microtubule architecture but do involve he promotion of cell cycle arrest and apoptosis. These are the first data confirming direct cytotoxic effects of DES and DESdP in prostate cancer cells via an apoptotic mechanism. Implications: These results suggest that DES and DESdP have potential value as agents against androgen-insensitive prostate neoplasms through induction of an apoptotic cascade. [J Natl Cancer Inst 1996; 88: 908–17]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kotha, M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A. S. Zervos, B. Carter, J. Turkson, and R. Jove Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., March 1, 2006; 5(3): 621 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.C.H. d'Ancona and F.M.J. Debruyne Endocrine approaches in the therapy of prostate carcinoma Hum. Reprod. Update, May 1, 2005; 11(3): 309 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Loblaw, D. S. Mendelson, J. A. Talcott, K. S. Virgo, M. R. Somerfield, E. Ben-Josef, R. Middleton, H. Porterfield, S. A. Sharp, T. J. Smith, et al. American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer J. Clin. Oncol., July 15, 2004; 22(14): 2927 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mobley, J. O. L'Esperance, M. Wu, C. J. Friel, R. H. Hanson, and S.-M. Ho The novel estrogen 17{alpha}-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17{beta}-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro Mol. Cancer Ther., May 1, 2004; 3(5): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Qiu, M. Ohe, N. Koibuchi, and S. Matsuzaki Apoptosis in the Epididymal Epithelium of Adult Male Golden Hamster Exposed to Diethylstilbestrol J. Histochem. Cytochem., February 1, 2004; 52(2): 187 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Do, S. Ryu, M. Nagarkatti, and P. S. Nagarkatti Role of Death Receptor Pathway in Estradiol-Induced T-Cell Apoptosis in Vivo Toxicol. Sci., November 1, 2002; 70(1): 63 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sovak, A. L. Seligson, M. Konas, M. Hajduch, M. Dolezal, M. Machala, and R. Nagourney Herbal Composition PC-SPES for Management of Prostate Cancer: Identification of Active Principles J Natl Cancer Inst, September 4, 2002; 94(17): 1275 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Cordell PC-SPES: A Brief Overview Integr Cancer Ther, September 1, 2002; 1(3): 271 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bonham, H. Arnold, B. Montgomery, and P. S. Nelson Molecular Effects of the Herbal Compound PC-SPES: Identification of Activity Pathways in Prostate Carcinoma Cancer Res., July 15, 2002; 62(14): 3920 - 3924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]
|
|
|
|
|
|
L. G. Horvath, S. M. Henshall, C-S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O'Neill, et al. Frequent Loss of Estrogen Receptor-{beta} Expression in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5331 - 5335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Lau, M. LaSpina, J. Long, and S.-M. Ho Expression of Estrogen Receptor (ER)-{{alpha}} and ER-{beta} in Normal and Malignant Prostatic Epithelial Cells: Regulation by Methylation and Involvement in Growth Regulation Cancer Res., June 1, 2000; 60(12): 3175 - 3182. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Can and O. Semiz Diethylstilbestrol (DES)-induced cell cycle delay and meiotic spindle disruption in mouse oocytes during in-vitro maturation Mol. Hum. Reprod., February 1, 2000; 6(2): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Wade, P. Oommen, W. C. Conner, D. J. Earnest, and R. C. Miranda Overlapping and Divergent Actions of Estrogen and the Neurotrophins on Cell Fate and p53-Dependent Signal Transduction in Conditionally Immortalized Cerebral Cortical Neuroblasts J. Neurosci., August 15, 1999; 19(16): 6994 - 7006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yoshida, R. R. Newbold, and D. Dixon Effects of Neonatal Diethylstilbestrol (DES) Exposure on Morphology and Growth Patterns of Endometrial Epithelial Cells in CD-1 Mice Toxicol Pathol, May 1, 1999; 27(3): 325 - 333. [Abstract] [PDF]
|
|
|
|
 |
|
 E. J. Small, J. Geliebter, R. Tiwari, J. M. Wu, R. S. DiPaola, W. N. Hait, and M. A. Gallo PC-SPES in Prostate Cancer N. Engl. J. Med., February 18, 1999; 340(7): 566 - 568. [Full Text]
|
|
|
|
|
|
R. S. DiPaola, H. Zhang, G. H. Lambert, R. Meeker, E. Licitra, M. M. Rafi, B. T. Zhu, H. Spaulding, S. Goodin, M. B. Toledano, et al. Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer N. Engl. J. Med., September 17, 1998; 339(12): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guo, S. Yu, A. T. Davis, H. Wang, J. E. Green, and K. Ahmed A Potential Role of Nuclear Matrix-associated Protein Kinase CK2 in Protection against Drug-induced Apoptosis in Cancer Cells J. Biol. Chem., February 16, 2001; 276(8): 5992 - 5999. [Abstract] [Full Text] [PDF]
|
|